Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data

Summary Background Intermediate or surrogate endpoints for survival can shorten time lines for drug approval. We aimed to assess circulating tumour cell (CTC) count as a prognostic factor for survival in patients with progressive, metastatic, castration-resistant prostate cancer receiving first-line...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The lancet oncology 2009-03, Vol.10 (3), p.233-239
Hauptverfasser:	Scher, Howard I, Prof, Jia, Xiaoyu, MS, de Bono, Johann S, MD, Fleisher, Martin, PhD, Pienta, Kenneth J, Prof, Raghavan, Derek, Prof, Heller, Glenn, PhD
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Aged, 80 and over Antigens Biomarkers Cancer therapies Chemotherapy Clinical medicine Clinical trials Clinical Trials as Topic Dehydrogenases Disease Hematology, Oncology and Palliative Medicine Hemoglobin Humans L-Lactate Dehydrogenase - blood Male Medical prognosis Metastasis Middle Aged Neoplastic Cells, Circulating Oncology Orchiectomy Patients Prognosis Prostate cancer Prostate-Specific Antigen - blood Prostatic Neoplasms - mortality Prostatic Neoplasms - pathology Scintigraphy Variables
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!